| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 689,892 | 652,800 | ||
| Accounts receivable, net | 106,409 | 65,863 | ||
| Inventory, net | 28,029 | 18,650 | ||
| Prepaid expenses and other current assets | 28,123 | 21,426 | ||
| Total current assets | 852,453 | 758,739 | ||
| Operating lease right-of-use asset, net | 2,010 | 2,084 | ||
| Property and equipment, net | 1,077 | 1,149 | ||
| Gross carrying value | 227,712 | - | ||
| Accumulated amortization | 99,073 | - | ||
| License and acquired intangibles, net | 128,639 | 137,983 | ||
| Deferred tax assets, net | 48,256 | 50,704 | ||
| Investment in equity securities | 19,167 | 21,256 | ||
| Total assets | 1,051,602 | 971,915 | ||
| Accounts payable | 9,096 | 5,528 | ||
| Accrued expenses and other liabilities | 119,639 | 107,479 | ||
| Total current liabilities | 128,735 | 113,007 | ||
| Operating lease liability, net of current portion | 2,461 | 2,572 | ||
| Other non-current liabilities | 161 | 309 | ||
| Total liabilities | 131,357 | 115,888 | ||
| Common stock, 0.001 par value, 200,000,000 shares authorized 123,264,583 shares and 120,879,099 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 123 | 122 | ||
| Additional paid-in capital | 473,333 | 461,868 | ||
| Retained earnings | 446,789 | 394,006 | ||
| Accumulated other comprehensive income (loss) (note 4) | 0 | 31 | ||
| Total stockholders' equity | 920,245 | 856,027 | ||
| Total liabilities and stockholders' equity | 1,051,602 | 971,915 | ||
CATALYST PHARMACEUTICALS, INC. (CPRX)
CATALYST PHARMACEUTICALS, INC. (CPRX)